Cyclopharm Ltd
ASX:CYC
Cyclopharm Ltd
Operating Income
Cyclopharm Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Operating Income
-AU$14.5m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
Somnomed Ltd
ASX:SOM
|
Operating Income
-AU$2.4m
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cochlear Ltd
ASX:COH
|
Operating Income
AU$536.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
10%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Operating Income
-AU$5.4m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-19%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Operating Income
AU$5.8m
|
CAGR 3-Years
13%
|
CAGR 5-Years
108%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Operating Income
-AU$5.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
Cyclopharm Ltd
Glance View
Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.
See Also
What is Cyclopharm Ltd's Operating Income?
Operating Income
-14.5m
AUD
Based on the financial report for Dec 31, 2024, Cyclopharm Ltd's Operating Income amounts to -14.5m AUD.
What is Cyclopharm Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
-34%
Over the last year, the Operating Income growth was -69%. The average annual Operating Income growth rates for Cyclopharm Ltd have been -48% over the past three years , -34% over the past five years .
You don't have any saved screeners yet